– USA, GA – Inhibikase Therapeutics, Inc. (NASDAQ: IKT), a clinical-stage pharmaceutical company, today announced the appointment of Gisele Dion to its Board of Directors, effective September 1, 2022.
Ms. Dion will also join the Audit Committee as chair, and the Compensation Committee as a member, replacing Elizabeth O’Farrell, retiring from the Board, effective immediately.
“I am excited to have Gisele join the Board of Inhibikase. She brings a wealth of public company experience having led financial, accounting, and M&A strategies across large pharma. We look forward to leveraging her expertise, which we believe complements our board, as we seek to improve the lives of patients suffering from devastating neurodegenerative and other Abl-kinase-dependent diseases,” said CEO, Dr. Milton Werner.
About Gisele Dion
Gisele Dion is currently a member of the Board of Directors at Cytek Biosciences and most recently served as an Audit Advisor Group Member for the Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, she served as the Senior Vice-President and CAO at Takeda Pharmaceuticals, advising the CFO and protecting assets, including $30B+ in revenue. While at Takeda, Ms. Dion successfully led the company through SEC registration and guided change management initiatives. Before Takeda, she was CAO and Corporate Controller at Shire Pharmaceuticals, where she spearheaded M&A integrations, SEC adherence, and GAAP compliance from 2016 to 2019 when it was acquired by Takeda. Earlier, Ms. Dion was a Corporate Controller at Biogen. Ms. Dion holds a B.S. in Accounting and Management Information Systems from Fairfield University.
“It is a privilege to join the Inhibikase team as the Company continues to advance its novel therapeutics in the clinic, providing hope for patients with Parkinson’s disease,” said Ms. Dion. “I am excited about Inhibikase’s approach that has the potential to alter the course of neurodegenerative diseases, such as Parkinson’s. Moreover, I look forward to bringing my extensive financial and accounting expertise to the table and helping guide the Company’s success.”
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified several follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
